Published in J Mol Histol on August 28, 2010
Mechanisms, function and clinical applications of DNp73. Cell Cycle (2013) 0.83
A novel dual signaling axis for NSP 5a3a induced apoptosis in head and neck carcinoma. Oncotarget (2011) 0.77
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell (1997) 7.27
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev (2008) 4.85
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
Chemosensitivity linked to p73 function. Cancer Cell (2003) 3.63
Aberrant subcellular localization of BRCA1 in breast cancer. Science (1995) 3.61
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A (1995) 2.56
DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med (2002) 2.48
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ (2001) 2.40
Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med (1998) 2.40
TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ (2005) 2.25
Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res (2003) 1.91
Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A (2004) 1.91
DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol (2005) 1.88
Regulation of p53 localization. Eur J Biochem (2001) 1.57
DeltaNp73beta is active in transactivation and growth suppression. Mol Cell Biol (2004) 1.56
The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63. J Biol Chem (2005) 1.49
Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res (2002) 1.47
Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res (2002) 1.41
Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem (2002) 1.37
C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer (2000) 1.37
p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene (2002) 1.36
Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst (1999) 1.36
deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol (2003) 1.33
New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene (1999) 1.30
The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg (2009) 1.27
Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ (1999) 1.20
Roles for p53 and p73 during oligodendrocyte development. Development (2004) 1.18
Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem (2006) 1.17
Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene (2001) 1.15
Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene (2003) 1.14
Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res (2004) 1.09
Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. J Biol Chem (1999) 1.06
Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo. Mol Cancer (2009) 1.06
Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer (2007) 1.05
Defining a role for Sonic hedgehog pathway activation in desmoplastic medulloblastoma by identifying GLI1 target genes. Int J Cancer (2009) 1.04
Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer (2006) 1.03
New antibodies recognizing p73: comparison with commercial antibodies. Biochem Biophys Res Commun (2005) 1.02
p73-alpha is capable of inducing scotin and ER stress. Oncogene (2004) 1.02
TAp73 is a downstream target of p53 in controlling the cellular defense against stress. J Biol Chem (2007) 1.01
p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J (2008) 1.01
P73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis. Oncogene (2008) 1.00
Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73. Carcinogenesis (2007) 1.00
The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells. J Cell Sci (2005) 0.99
Embryonal neural tumours and cell death. Apoptosis (2009) 0.97
Nuclear import and export signals in control of the p53-related protein p73. J Biol Chem (2002) 0.95
Subcellular distribution of p53 and p73 are differentially regulated by MDM2. Cancer Res (2001) 0.94
Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin. Cell Cycle (2007) 0.93
Binding of the C-terminal sterile alpha motif (SAM) domain of human p73 to lipid membranes. J Biol Chem (2003) 0.93
Multiple isoforms of the tumor protein p73 are expressed in the adult human telencephalon and choroid plexus and present in the cerebrospinal fluid. Eur J Neurosci (2006) 0.93
TAp73beta and DNp73beta activate the expression of the pro-survival caspase-2S. Nucleic Acids Res (2008) 0.93
Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer (1999) 0.90
The p53 homologue p73 accumulates in the nucleus and localizes to neurites and neurofibrillary tangles in Alzheimer disease brain. Neuropathol Appl Neurobiol (2004) 0.90
Novel in vivo targets of DeltaNp63 in keratinocytes identified by a modified chromatin immunoprecipitation approach. BMC Mol Biol (2007) 0.89
Regulation of p73 by Hck through kinase-dependent and independent mechanisms. BMC Mol Biol (2007) 0.89
p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res (2003) 0.87
Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. Histopathology (2006) 0.87
p73 expression in medulloblastoma: TAp73/DeltaNp73 transcript detection and possible association of p73alpha/DeltaNp73 immunoreactivity with survival. Acta Neuropathol (2007) 0.87
DeltaN-p73alpha accumulates in human neuroblastic tumors. Am J Pathol (2002) 0.87
Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene (2009) 0.86
DeltaNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. Cell Death Differ (2004) 0.85
p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance. J Mol Histol (2007) 0.83
Differential expression of p53, p63 and p73 proteins in human buccal squamous-cell carcinomas. Clin Otolaryngol Allied Sci (2003) 0.82
Filamin A negatively regulates the transcriptional activity of p73alpha in the cytoplasm. Biochem Biophys Res Commun (2007) 0.81
p73 protein expression correlates with radiation-induced apoptosis in the lack of p53 response to radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys (2008) 0.81
Different intracellular compartmentalization of TA and DeltaNp73 in non-small cell lung cancer. Int J Oncol (2009) 0.80
Evaluation of p63 and p73 antibodies for cross-reactivity. Cell Cycle (2009) 0.80
Up-regulation of NFkappaB-responsive gene expression by DeltaNp73alpha in p53 null cells. Exp Cell Res (2006) 0.79
p73 and p53 pathway in human breast cancers. J Clin Oncol (2007) 0.78
Amphiphysin IIb-1, a novel splicing variant of amphiphysin II, regulates p73beta function through protein-protein interactions. Oncogene (2001) 0.76
The presence of an intronic deletion in p73 and high levels of ZEB1 alter the TAp73/DeltaTAp73 ratio in colorectal carcinomas. J Pathol (2006) 0.76
Cell density-dependent regulation of p73 in breast cancer cells. Int J Oncol (2009) 0.76
Comparative analysis of an experimental subcellular protein localization assay and in silico prediction methods. J Mol Histol (2009) 0.75
Over-expression of p73beta results in apoptotic death of post-mitotic hNT neurons. J Neurol Sci (2005) 0.75
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
A case of anaplastic large cell lymphoma-induced hemophagocytic lymphohistiocytosis in an adolescent female. Pediatr Blood Cancer (2007) 1.48
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Malignant intracranial germinoma in Smith-Lemli-Opitz syndrome: cholesterol homeostasis possibly connecting morphogenesis and cancer development. J Pediatr Hematol Oncol (2008) 1.42
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie (2006) 1.03
Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance? Neuropathology (2011) 0.97
Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma. J Neurooncol (2010) 0.95
Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature. Pediatr Dev Pathol (2010) 0.94
Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines. BMC Cancer (2008) 0.92
Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol (2008) 0.92
Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Transl Oncol (2011) 0.92
Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. Haematologica (2010) 0.91
Dissemination of IncFII(K)-type plasmids in multiresistant CTX-M-15-producing Enterobacteriaceae isolates from children in hospital paediatric oncology wards. Int J Antimicrob Agents (2012) 0.91
Analysis of nuclear nestin localization in cell lines derived from neurogenic tumors. Tumour Biol (2011) 0.89
p73 expression in medulloblastoma: TAp73/DeltaNp73 transcript detection and possible association of p73alpha/DeltaNp73 immunoreactivity with survival. Acta Neuropathol (2007) 0.87
Screening of genomic imbalances in glioblastoma multiforme using high-resolution comparative genomic hybridization. Oncol Rep (2007) 0.86
Influence of LOX/COX inhibitors on cell differentiation induced by all-trans retinoic acid in neuroblastoma cell lines. Int J Mol Med (2010) 0.85
Treatment of deep venous thrombosis with low molecular weight heparin in pediatric cancer patients: safety and efficacy. Blood Coagul Fibrinolysis (2009) 0.84
Recurrent laryngeal papillomatosis: successful treatment with human papillomavirus vaccination. Arch Dis Child (2011) 0.83
Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis. Haematologica (2011) 0.83
CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines. Anal Cell Pathol (Amst) (2011) 0.82
Enhancement of ATRA-induced differentiation of neuroblastoma cells with LOX/COX inhibitors: an expression profiling study. J Exp Clin Cancer Res (2010) 0.82
Anti-angiogenic therapies for children with cancer. Curr Cancer Drug Targets (2010) 0.81
Homocysteine: exploring its potential as a pharmacodynamic biomarker of antifolate chemotherapy. Pharmacogenomics (2004) 0.80
EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy. Oncol Rep (2013) 0.80
Successful treatment of life-threatening Candida peritonitis in a child with abdominal non-Hodgkin lymphoma using Efungumab and amphotericin B colloid dispersion. J Pediatr Hematol Oncol (2010) 0.80
Extension of microRNA expression pattern associated with high-risk neuroblastoma. Tumour Biol (2013) 0.79
Multifunctional immune-modulatory protein HLA-E identified in classical Hodgkin lymphoma: possible implications. Pathol Res Pract (2011) 0.79
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun (2014) 0.79
Differentiation of HL-60 myeloid leukemia cells induced by all-trans retinoic acid is enhanced in combination with caffeic acid. Int J Mol Med (2004) 0.78
Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B. Clin Adv Hematol Oncol (2009) 0.78
Nestin expression in high-grade osteosarcomas and its clinical significance. Oncol Rep (2012) 0.77
Intracellular distribution of the ΔNp73 protein isoform in medulloblastoma cells: a study with newly generated rabbit polyclonal antibodies. Histol Histopathol (2013) 0.77
LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines. Tumour Biol (2014) 0.77
High-dose methotrexate in pediatric oncology-back to bench from bedside for a while? J Pediatr Hematol Oncol (2009) 0.77
The role of actin in the apoptotic cell death of P19 embryonal carcinoma cells. Int J Oncol (2005) 0.76
Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry. J Antimicrob Chemother (2008) 0.75
Augmenting clinical interpretability of thiopurine methyltransferase laboratory evaluation. Oncology (2014) 0.75
Inflammatory myofibroblastic tumor of the esophagus in childhood: a case report and a review of the literature. J Pediatr Hematol Oncol (2015) 0.75
Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols. Blood Coagul Fibrinolysis (2012) 0.75
Specific cytoskeleton changes during apoptosis accompanying induced differentiation of HL-60 myeloid leukemia cells. Oncol Rep (2003) 0.75
Extraosseal Ewing sarcoma as a rare cause of the blueberry muffin baby syndrome: a case report and the review of the literature. Am J Dermatopathol (2011) 0.75
Langerhans Cell Histiocytosis: The Time has Come to Consider a CNS-directed Prophylactic Approach. J Pediatr Hematol Oncol (2016) 0.75
Chylothorax as a possible diagnostic pitfall: a report of 2 cases with cytologic findings. Acta Cytol (2005) 0.75
An unusual loss of EGFR gene copy in glioblastoma multiforme in a child: a case report and analysis of a successfully derived HGG-02 cell line. Childs Nerv Syst (2010) 0.75